EDIT Stock Overview
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Editas Medicine, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.61 |
| 52 Week High | US$11.91 |
| 52 Week Low | US$5.85 |
| Beta | 2.02 |
| 1 Month Change | -27.33% |
| 3 Month Change | -31.33% |
| 1 Year Change | -30.66% |
| 3 Year Change | -84.36% |
| 5 Year Change | -79.23% |
| Change since IPO | -69.18% |
Recent News & Updates
Recent updates
Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement
Mar 09
Editas Medicine: Several Catalysts For Reni-Cel In 2024 Make This A Must Watch
Feb 28New Forecasts: Here's What Analysts Think The Future Holds For Editas Medicine, Inc. (NASDAQ:EDIT)
Dec 15Broker Revenue Forecasts For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher
May 10Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?
Jan 19Editas Medicine gains on report of potential sale of pre-clinical cancer pipeline
Oct 18Editas Medicine started at neutral at BofA due to competition in gene editing programs
Sep 29We're Hopeful That Editas Medicine (NASDAQ:EDIT) Will Use Its Cash Wisely
Sep 13Editas: End Of Year Data Readouts For SCD And Rare Eye Disease Studies
Aug 23Editas Medicine Q2 2022 Earnings Preview
Aug 02Baisong Mei joins Editas Medicine as Chief Medical Officer
Jul 18Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Deliver On Growth Plans?
Jun 12Editas: Tackling Rare Eye Disease With Use Of Crispr Technology
Jun 06Editas: The Unforeseen Detrimental Effect Of Patent Win
Mar 25Editas: CRISPR Gene Editing Biotech With Promising Future
Mar 15Analysts' Revenue Estimates For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher
Feb 25Editas Medicine: A Gene-Editing Company That Has Fallen Significantly In Price Recently
Dec 28Editas - The Introvert Crispr Biotech Too Shy To Flex Its Muscles
Dec 15Here's Why We're Not Too Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Situation
Nov 17Editas: Data Was Eagerly Anticipated But Failed To Impress
Nov 03Is Editas Medicine (NASDAQ:EDIT) Using Too Much Debt?
Sep 07Editas: Gene Therapy Specialist Leading The Way In Eye Disease
Aug 27Here's Why We're Not Too Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Situation
Aug 12Shareholder Returns
| EDIT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -15.4% | -4.2% | -3.7% |
| 1Y | -30.7% | -2.0% | 20.5% |
Return vs Industry: EDIT underperformed the US Biotechs industry which returned -2% over the past year.
Return vs Market: EDIT underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| EDIT volatility | |
|---|---|
| EDIT Average Weekly Movement | 11.5% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: EDIT's share price has been volatile over the past 3 months.
Volatility Over Time: EDIT's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 265 | Gilmore O’Neill | www.editasmedicine.com |
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.
Editas Medicine, Inc. Fundamentals Summary
| EDIT fundamental statistics | |
|---|---|
| Market cap | US$481.07m |
| Earnings (TTM) | -US$153.22m |
| Revenue (TTM) | US$78.12m |
5.9x
P/S Ratio-3.0x
P/E RatioIs EDIT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EDIT income statement (TTM) | |
|---|---|
| Revenue | US$78.12m |
| Cost of Revenue | US$177.65m |
| Gross Profit | -US$99.53m |
| Other Expenses | US$53.69m |
| Earnings | -US$153.22m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.86 |
| Gross Margin | -127.40% |
| Net Profit Margin | -196.13% |
| Debt/Equity Ratio | 0% |
How did EDIT perform over the long term?
See historical performance and comparison